Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.53 |
| ▸ | BCR | P11274 | 5/20 | 0.51 |
| ▸ | BRAF | P15056 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | LCK | P06239 | 3/20 | 0.45 |
| ▸ | TEK | Q02763 | 3/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.44 |
| ▸ | LDLR | P01130 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 2/20 | 0.42 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1078917 | 0.90 | ABL1 (0.58) | ABL1BCRBRAFSRCNR2E1 | |
| SCHEMBL1078714 | 0.81 | LCK (0.63) | ABL1BRAFSRCMAPK14KDR | |
| SCHEMBL1078661 | 0.81 | LCK (0.47) | ABL1BRAFSRCMAPK14KDR | |
| SCHEMBL1075954 | 0.81 | BRAF (0.55) | BRAFKITDDR1DDR2 | |
| SCHEMBL1082660 | 0.80 | DDR2 (0.60) | ABL1BCRBRAFSRCKIT | |
| SCHEMBL13771827 | 0.80 | ABL1 (0.56) | ABL1BCRBRAFSRCMAPK14 | |
| SCHEMBL1079653 | 0.79 | DDR2 (0.51) | ABL1BRAFSRCMAPK14KDR | |
| SCHEMBL1149056 | 0.79 | LCK (0.42) | ABL1BRAFMAPK14KDRLCK | |
| SCHEMBL1076129 | 0.78 | RAF1 (0.51) | BRAFMAPK14KDRLCKTEK | |
| SCHEMBL1080474 | 0.78 | ABL1 (0.54) | ABL1BCRBRAFSRCNR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269993-B1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | H1-2, H1-3, H1-0 | ABL1 47/4885BCR 3233/4885BRAF 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.